Raymond E. Cabillot Sells 1,100 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,100 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $45.01, for a total transaction of $49,511.00. Following the sale, the director now directly owns 318,652 shares in the company, valued at approximately $14,342,526.52. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Pro-Dex Price Performance

Shares of NASDAQ PDEX traded down $2.76 during trading on Monday, hitting $35.22. 5,716 shares of the company were exchanged, compared to its average volume of 30,806. Pro-Dex, Inc. has a 1 year low of $16.18 and a 1 year high of $59.60. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The firm’s fifty day moving average price is $47.43 and its 200 day moving average price is $34.74. The company has a market cap of $114.80 million, a price-to-earnings ratio of 17.73 and a beta of 0.53.

Pro-Dex (NASDAQ:PDEX) last announced its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, sell-side analysts expect that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PDEX. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th. Ascendiant Capital Markets lifted their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PDEX. Dimensional Fund Advisors LP increased its stake in shares of Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after acquiring an additional 3,067 shares during the last quarter. Renaissance Technologies LLC increased its position in Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares in the last quarter. Bard Associates Inc. increased its position in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after purchasing an additional 2,031 shares in the last quarter. FMR LLC increased its position in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares in the last quarter. Institutional investors and hedge funds own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.